首页> Journal of clinical oncology : official journal of the American Society of Clinical Oncology> Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.

导出 OA

翻译打印收藏纠错

第一作者： Matthew S,Davids

第一单位： Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

作者： Matthew S,Davids ^[1] ; Christine E,Ryan ^[1] ; Benjamin L,Lampson ^[1] ; Yue,Ren ^[2] ; Svitlana,Tyekucheva ^[2] ; Stacey M,Fernandes ^[1] ; Jennifer L,Crombie ^[1] ; Austin I,Kim ^[1] ; Matthew,Weinstock ^[3] ; Josie,Montegaard ^[1] ; Heather A,Walker ^[1] ; Claire,Greenman ^[1] ; Victoria,Patterson ^[1] ; Caron A,Jacobson ^[1] ; Ann S,LaCasce ^[1] ; Philippe,Armand ^[1] ; David C,Fisher ^[1] ; Steve,Lo ^[4] ; Adam J,Olszewski ^[5] ; Jon E,Arnason ^[3] ; Inhye E,Ahn ^[1] ; Jennifer R,Brown ^[1]

作者单位： Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. ^[1] Department of Data Science, Dana-Farber Cancer Institute, Boston, MA. ^[2] Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA. ^[3] Stamford Hospital, Stamford, CT. ^[4] Brown University Health, Providence, RI. ^[5]